Author

D. Venkatesan

Observed names: Dev Sudersan Venkatesan, Dev Sudersan Venkatesan, Venkatesan, Dev Sudersan

Institutions: SRM Institute of Science and Technology, SRM Medical College Hospital and Research Centre

Observed institutions: SRM Institute of Science and Technology, SRM Medical College Hospital and Research Centre

ORCID: 0000-0001-9662-5459

Observed ORCID: 0000-0001-9662-5459

OpenAlex ID: A5110242733

Mutant TP53 Physically Sequesters FOXP3 to Abrogate PD-L1 Transcriptional Regulation and Drive Immune Evasion in Lung Adenocarcinoma: A Multi-Scale Computational Proof

2026 · Dev Sudersan Venkatesan · Research Square · 2

Mutant TP53 differentially rewires FOXP3-mediated immune checkpoint regulation in a cancer lineage-dependent manner: a comprehensive pan-cancer computational analysis

2026 · Dev Sudersan Venkatesan · Research Square · 1

Mutant TP53 Hotspot Variants Differentially Rewire the Caspase Regulatory Network Across Cancer Lineages: A Pan-Cancer Computational Pharmacology Analysis

2026 · Dev Sudersan Venkatesan · Research Square · 1

Mutant TP53 physically sequesters FOXP3 to abrogate PD-L1 transcriptional regulation and drive immune evasion in lung adenocarcinoma: multi-scale computational evidence supporting a candidate interaction

2026 · Dev Sudersan Venkatesan · BMC Bioinformatics

Lineage-Specific Rewiring of the JAK-STAT Signalling Axis by Mutant TP53 Drives Pan-Cancer Immune Evasion: A Comprehensive Analysis of 5,775 TCGA Samples

2026 · Dev Sudersan Venkatesan · Research Square

The Global Compatibility Index (GCI): A Variance-Weighted Pharmacogenomic Scoring System Demonstrates Near-Perfect Cross-Mode Consistency (ICC = 0.994) and Improves Warfarin Dose Prediction Over the CPIC Algorithm in 5,475 Patients Across Four Continents, with Multi-Drug Validation Across 10 Independent Datasets

2026 · Dev Sudersan Venkatesan · Research Square

Accessible CKD Risk Index (ACRI): A Genetically Anchored, Mechanistically Validated, Income-Agnostic Early Detection Score for Chronic Kidney Disease - A Pan-Cohort Study Across Five Global Income Settings

2026 · Dev Sudersan Venkatesan, Marina Andavar · Research Square

ABO Blood Group-Based Disease Stratification as a Complementary Layer for p53-Driven Cancer Risk Models: A Meta-Analytic and Global Simulation Study

2026 · Dev Sudersan Venkatesan · Research Square

p53 as a Convergent Genetic Modifier in Chronic Kidney Disease: Unifying the Secondary Risk Gene Landscape and Defining the Conceptual Basis for Renal Modulatory Drugs (RMDs)

2026 · Venkatesan, Dev Sudersan · Zenodo (CERN European Organization for Nuclear Research)

Serial high-sensitivity troponin I monitoring as a prognostic marker in acute ischemic stroke

2026 · Nirmala Devi Chandrasekaran, Abinaya P.V., et al. · European Journal of Clinical and Experimental Medicine

Mutant TP53 Differentially Rewires FOXP3-Mediated Immune Checkpoint Regulation in a Cancer Lineage-Dependent Manner: A Comprehensive Pan-Cancer Computational Analysis

2026 · Venkatesan, Dev Sudersan · Zenodo (CERN European Organization for Nuclear Research)

p53 as a Convergent Genetic Modifier in Chronic Kidney Disease: Unifying Genetic Risk and Defining Renal Modulatory Drugs

2026 · Dev Sudersan Venkatesan · Research Square

Open rings of demyelination – a rare case of tumefactive multiple sclerosis

2025 · Parameswaran K., Sai Manasa Nemani, et al. · European Journal of Clinical and Experimental Medicine

The Efficacy of Imeglimin Compared to Metformin in Dual Therapy with DPP-4 Inhibitor on Glycemic Control and Weight Management: A Randomized Controlled Trial

2024 · Dev Sudersan Venkatesan, Aparna Chandrasekaran, et al. · SSRN Electronic Journal

Works count: 14

Citation count: 4

H-index: 1

I10-index: